American Century Companies Inc. Boosts Position in Dynavax Technologies Co. (NASDAQ:DVAX)

American Century Companies Inc. boosted its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 261,802 shares of the biopharmaceutical company's stock after purchasing an additional 26,135 shares during the period. American Century Companies Inc. owned about 0.20% of Dynavax Technologies worth $3,343,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Dynavax Technologies during the fourth quarter worth about $990,000. Nordea Investment Management AB increased its stake in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $275,000. Barclays PLC lifted its stake in Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DVAX has been the subject of a number of analyst reports. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Trading Up 2.6 %

Shares of DVAX stock traded up $0.28 during mid-day trading on Friday, hitting $11.25. 2,119,183 shares of the company's stock were exchanged, compared to its average volume of 2,209,754. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 62.50 and a beta of 1.26. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The stock has a 50-day simple moving average of $13.20 and a two-hundred day simple moving average of $12.58.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Equities analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.